-
New Brunswick Scientific Announces New Large-Capacity ULT Freezer
9/6/2010
New Brunswick Scientific has added a new large-capacity, upright ultra-low temperature (-86°C) freezer to its expansive line, capable of storing up to 48,000 samples.
-
Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
9/6/2010
Pfenex Inc. and Cedarlane recently announced that they have entered into a non-exclusive distribution agreement. Cedarlane will market and distribute high value reagent proteins produced by Pfenex to researchers in Canada and the United States. Among the products initially distributed will be vaccine carrier proteins such as CRM197 and Cholera Toxin B and cell culture related growth factors including G-CSF and Interferon beta 1-b.
-
Tibotec Pharmaceuticals Seeks European Marketing Authorization For Investigational Once-Daily HIV Treatment TMC278
9/6/2010
Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV.
-
ForteBio Announces Launch Of Protein G Biosensor For Use On Company's Octet® Instruments
9/6/2010
ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution.
-
Lord Lieutenant Presents 2010 Queen’s Award To Malvern Instruments
9/6/2010
Sir Michael Brinton, the Lord Lieutenant of Worcestershire, today formally presented the 2010 Queen's Award for Enterprise in Innovation to materials characterization company Malvern Instruments in a ceremony held at its UK headquarters and attended by employees from all parts of the organisation.
-
BMG LABTECH Introduces A Revolution In Absorbance Reading - SPECTROstar Nano
9/5/2010
Experience the future of microplate reader technology today with the new SPECTROstar Nano.
-
Radient Pharmaceuticals Resumes Collaboration To Advance Its Onko-Sure® In Vitro Diagnostic Cancer Test In The USA
9/2/2010
Radient Pharmaceuticals Corporation (RPC) /quotes/comstock/14*!rpc/quotes/nls/rpc (RPC 0.68, +0.00, +0.03%) announced today it has resumed collaborations with Mayo Collaborative Services, Inc. to conduct a clinical study for the validation of RPC's US FDA-approved Onko-Sure(R) in vitro diagnostic (IVD) cancer test as a useful tool in colorectal cancer (CRC) recurrence and treatment monitoring.
-
Addex Drug-Candidate Effective In Alzheimer’s Disease Model
9/2/2010
Allosteric modulation company Addex Pharmaceuticals Ltd (SIX: ADXN) announced today that it has observed efficacy in a model of Alzheimer's disease using a recently discovered orally-available drug-candidate. The proprietary molecule specifically inhibits a receptor subtype called the metabotropic glutamate receptor 2 (mGluR2) via negative allosteric modulation (NAM). An Addex mGluR2 NAM is scheduled to enter Phase I clinical testing in healthy volunteers during 2011.
-
Halozyme Begins Phase 2 Clinical Trials With Insulin Analogs Lispro and Aspart With rHuPH20 In Type 1 And Type 2 Diabetes
9/2/2010
Halozyme Therapeutics, Inc. (Nasdaq:
HALO) today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
-
QRxPharma Announces Interim Analysis Of Final Pivotal Phase 3 Study For MoxDuo®IR
9/2/2010
QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission. The analysis indicated the planned sample size of 140 patients has greater than 90% power to detect differences of analgesic effect, indicating there is no need to enrol additional patients.
